Science

Line blot for myositis shows high agreement with biopsy

A multiparameter EUROLINE blot for detection of myositis-related autoantibodies showed a high agreement with muscle biopsy results in patients with idiopathic inflammatory myopathies (IIM), suggesting it can be used as a first-line diagnostic tool in the diagnostic workflow. The recently published study was performed as part of a collaboration between scientists from EUROIMMUN Brazil and […]

Science

Role of Epstein-Barr virus in multiple sclerosis

The frequency of intrathecal antibody production to Epstein-Barr virus (EBV) in multiple sclerosis (MS) patients is surprisingly low compared to that of other microbial agents. This was shown in a collaborative study between EUROIMMUN and scientists at Charité Universitätsmedizin Berlin. The finding is intriguing given the strong link between EBV and MS. EBV is presumed

Science

SARS-CoV-2 vaccine safety in an autoimmunity-prone population

A new study has shown that mRNA vaccines against SARS-CoV-2 do not induce short-term worsening of autoimmunity in patients with autoimmune liver diseases (AILD). The collaborative study between EUROIMMUN and researchers at the Epatocentro Ticino, Lugano and other institutes and clinics in Switzerland was published recently in the Journal of Autoimmunity. The mRNA vaccines against

Science

Serum uromodulin may indicate acute kidney injury in COVID-19 patients

Serum uromodulin (sUmod) represents a promising biomarker for acute kidney injury (AKI) in COVID-19 patients, as reported in a published collaborative study between EUROIMMUN, St Georg Hospital (Leipzig, Germany) and further institutes and clinics. AKI is a frequent complication in patients hospitalized with COVID-19 and is associated with an increased risk of fatal outcomes. Early

Science

Novel autoantibody against DAGLA discovered in cerebellitis

Diacylglycerol lipase alpha (DAGLA) has been identified as a novel autoantibody target in patients with rapid progressive cerebellar ataxia. The autoantibodies were characterised as part of a collaborative study between scientists at EUROIMMUN (Lübeck, Germany), the Hannover Medical School, (Hannover, Germany) and further institutes and clinics. The study was published in April 2024 the journal

Scroll to Top